Literature DB >> 6520836

The lifetime economic costs of rheumatoid arthritis.

C E Stone.   

Abstract

The lifetime economic costs of rheumatoid arthritis (RA) were estimated in a cohort with initial onset of RA in 1977. These costs included medical care expenses as well as the costs associated with illness-related work loss, overall and by age/sex category. The present value of the lifetime economic costs of RA was estimated to be $20,412/case in 1977 dollars, which is nearly as great as that for stroke and coronary heart disease. The study also highlighted the need for improved data on disease incidence, treatment costs, and survival experience of RA patients.

Entities:  

Mesh:

Year:  1984        PMID: 6520836

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  The treatment of rheumatoid arthritis: a review of recent clinical trials.

Authors:  T Mikuls; L Moreland
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

2.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

Review 3.  International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review.

Authors:  Hubertus Rosery; Rito Bergemann; Stefanie Maxion-Bergemann
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Pharmacoeconomics of nonsteroidal anti-inflammatory drugs (NSAIDs).

Authors:  H A Wynne; M Campbell
Journal:  Pharmacoeconomics       Date:  1993-02       Impact factor: 4.981

Review 5.  The costs of rheumatoid arthritis.

Authors:  S H Allaire; M J Prashker; R F Meenan
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 6.  The underestimated long term medical and economic consequences of rheumatoid arthritis.

Authors:  T Pincus
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 7.  An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.

Authors:  Nick J Bansback; Dean A Regier; Roberta Ara; Alan Brennan; Kamran Shojania; John M Esdaile; Aslam H Anis; Carlo A Marra
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Patient participation in service improvement: the initial Measures Project experience.

Authors:  A. Millett; J. Devlin; P. Adams; B. Gill
Journal:  Health Expect       Date:  1999-12       Impact factor: 3.377

9.  The economic impact of musculoskeletal disorders.

Authors:  P Lee
Journal:  Qual Life Res       Date:  1994-12       Impact factor: 4.147

10.  Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era.

Authors:  Erika Catay; Cecilia Castel Del Cid; Lorena Narváez; Edson J Velozo; Javier E Rosa; Luis J Catoggio; Enrique R Soriano
Journal:  Clinicoecon Outcomes Res       Date:  2012-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.